Premium
Structured treatment interruption in patients with alveolar echinococcosis
Author(s) -
Reuter Stefan,
Buck Andreas,
Manfras Burkhard,
Kratzer Wolfgang,
Seitz Hanns Martin,
Darge Kassa,
Reske Sven Norbert,
Kern Peter
Publication year - 2004
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.20078
Subject(s) - medicine , discontinuation , positron emission tomography , echinococcus multilocularis , lesion , echinococcosis , alveolar echinococcosis , prospective cohort study , asymptomatic , radiology , nuclear medicine , gastroenterology , surgery
In human alveolar echinococcosis (AE), benzimidazoles are given throughout life because they are only parasitostatic. It has been a longstanding goal to limit treatment, and recent reports suggest that, in selected cases, benzimidazoles may be parasitocidal. Previously, we showed that positron –emission tomography (PET) using [ 18 F]fluoro‐deoxyglucose discriminates active from inactive lesions in AE. We have now performed a 3‐year prospective study in 23 patients and conducted a structured treatment interruption in those without signs of PET activity. Disease progression was further assessed by ultrasound, computerized tomography, laboratory parameters, and clinical examination.We found PET‐negative lesions in 15 of 23 patients and benzimidazoles were discontinued in these patients. After 18 months, patients were reevaluated, and, of the 15 initially PET‐negative patients, 8 showed either new activity on PET (n = 6) or signs of clinical progression (n = 2). Reinitiation of benzimidazoles halted parasite growth again. No further progression was detected after 36 months. PET had a sensitivity of 91% for the detection of active lesions. In conclusion, despite successful suppression of metabolic activity, in most cases benzimidazoles do not kill the parasite. PET is a reliable tool for assessing metabolic activity and for timely detection of relapses. Neither duration of treatment, kind of treatment, lesion size, calcifications, or regressive changes reliably indicate parasite death. We discourage the discontinuation of benzimidazoles in inoperable AE even after many years of treatment. However, patients with a poor compliance of benzimidazole intake or patients suffering from side effects to benzimidazoles might be assessed for PET negativity. If permanent discontinuation of benzimidazoles is attempted, the course of disease should be followed by PET. (H EPATOLOGY 2004;39:509–517.)